| Issue Date | Title | Author(s) |
| Mar-2021 | Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial | Zhou, Caicun; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, LiZhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, QiMing; Cheng, Ying; Wu, Fengying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, XiaoRong; Zhang, Tao; Shi, Wei; Zou, Jianjun |
| Jul-2023 | Chinese expert consensus recommendations for the administration of immune checkpoint inhibitors to special cancer patient populations | Wang, Jun; Zhang, Bicheng; Peng, Ling; Liu, Xiufeng; Sun, Jianguo; Su, Chunxia; Wang, Huijuan; Zhao, Zheng; Si, Lu; Duan, Jianchun; Zhang, Hongmei; Li, Mengxia; Zhu, Bo; Zhang, Li; Li, Jin; Guo, Jun; Luo, Rongcheng; Qiu, Wensheng; Ye, Dingwei; Chu, Qian; Cui, Jiuwei; Dong, Xiaorong; Fan, Yun; Gao, Quanli; Guo, Ye; He, Zhiyong; Li, Wenfeng; Lin, Gen; Liu, Lian; Liu, Yutao; Qin, Haifeng; Ren, Shengxiang; Ren, Xiubao; Wang, Yongsheng; Xue, Junli; Yang, Yunpeng; Yang, Zhenzhou; Yue, Lu; Zhan, Xianbao; Zhang, Junping; Ma, Jun; Qin, Shukui; Wang, Baocheng |
| Jul-2021 | D-0316 in patients with advanced T790M-positive EGFR-mutant non-small cell lung cancer who progressed on prior EGFR-TKI therapy: results from a phase II study (NCT03861156). | Lu, Shun; Zhang, Yiping; Zhang, Guojun; Zhou, Jianying; Cang, Shundong; Cheng, Ying; Wu, Gang; Cao, Peiguo; Lv, Dongqing; Jin, Xiangming; Jian, Hong; Chen, Chengshui; Jiang, Guanming; Tian, Panwen; Wang, Kai; Zhao, Hui; Chen, Gongyan; Chen, Qun; Ding, Cuimin; Yang, Junquan; Guo, Renhua; Sun, Guoping; Wang, Bin; Jiang, Liyan; Zhuang, Wu; Liu, Zhe; Fang, Jian; Liu, Yunpeng; Zhang, Jian; Chen, Jun; Pan, Yueyin; Yu, Qitao; Zhao, Min; Cui, Jiuwei; Li, Dianming; Yi, Tienan; Yu, Zhuang; Yang, Yan; Zhang, Yan; Zhi, Xiuyi; Huang, Yunchao; Wu, Rong; Chen, Liangan; Zang, Aimin; Cao, Lejie; Li, Qingshan; Li, Xiaoling; Song, Yong; Wang, Donglin; Zhang, Shucai |
| Aug-2021 | Efficacy and Safety of Niraparib as Maintenance Treatment in Patients With Extensive-Stage SCLC After First-Line Chemotherapy: A Randomized, Double-Blind, Phase 3 Study | Ai, Xinghao; Pan, Yueyin; Shi, Jianhua; Yang, Nong; Liu, Chunling; Zhou, Jianying; Zhang, Xiaodong; Dong, Xiaorong; He, Jianxing; Li, Xiaoling; Chen, Gongyan; Li, Xingya; Zhang, Helong; Liao, Wangjun; Zhang, Yiping; Ma, Zhiyong; Jiang, Liyan; Cui, Jiuwei; Hu, Chunhong; Wang, Wei; Huang, Cheng; Zhao, Jun; Ding, Cuimin; Hu, Xiaohua; Wang, Kai; Gao, Beili; Song, Yong; Liu, Xiaoqing; Xiong, Jianping; Liu, Anwen; Li, Junling; Liu, Zhe; Li, Yinyin; Wang, Mengzhao; Zhang, Biao; Zhang, Dan; Lu, Shun |
| 30-Jun-2023 | Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial | Lu, Shun; Pan, Hongming; Wu, Lin; Yao, Yu; He, Jianxing; Wang, Yan; Wang, Xiuwen; Fang, Yong; Zhou, Zhen; Wang, Xicheng; Cai, Xiuyu; Yu, Yan; Ma, Zhiyong; Min, Xuhong; Yang, Zhixiong; Cao, Lejie; Yang, Huaping; Shu, Yongqian; Zhuang, Wu; Cang, Shundong; Fang, Jian; Li, Kai; Yu, Zhuang; Cui, Jiuwei; Zhang, Yang; Li, Man; Wen, Xinxuan; Zhang, Jie; Li, Weidong; Shi, Jianhua; Xu, Xingxiang; Zhong, Diansheng; Wang, Tao; Zhu, Jiajia |
| 1-Jan-2021 | Flumatinib versus Imatinib for Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia: A Phase III, Randomized, Open-label, Multi-center FESTnd Study | Zhang, Li; Meng, Li; Liu, Bingcheng; Zhang, Yanli; Zhu, Huanling; Cui, Jiuwei; Sun, Aining; Hu, Yu; Jin, Jie; Jiang, Hao; Zhang, Xi; Li, Yan; Liu, Li; Zhang, Wanggang; Liu, Xiaoli; Gu, Jian; Qiao, Jianhui; Ouyang, Guifang; Liu, Xin; Luo, Jianmin; Jiang, Ming; Xie, Xiaobao; Li, Jianyong; Zhao, Chunting; Zhang, Mei; Yang, Tonghua; Wang, Jianxiang |
| 2019 | Frontline flumatinib versus imatinib in patients with chronic myeloid leukemia in chronic phase: Results from the China randomized phase III study. | Li, Zhang; Meng, Li; Zhang, Yanli; Zhu, Huanling; Cui, Jiuwei; Sun, Aining; Hu, Yu; Jin, Jie; Jiang, Hao; Zhang, Xi; Li, Yan; Liu, Qifa; Liu, Li; Zhang, Wanggang; Gu, Jian; Qiao, Jian-Hui; Liu, Bingcheng; Zhang, Fengkui; Guo, Yong; Wang, Jianxiang |
| 2012 | Gaining a comprehensive understanding of pruritus | Zhang, Haiiao; Yang, Yi; Cui, Jiuwei; Zhang, Yaqin |
| Nov-2022 | Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non-small-cell lung cancer characterizes the features of response to PD-1 blockade plus chemotherapy | Wu, Fengying; Jiang, Tao; Chen, Gongyan; Huang, Yunchao; Zhou, Jianying; Lin, Lizhu; Feng, Jifeng; Wang, Zhehai; Shu, Yongqian; Shi, Jianhua; Hu, Yi; Wang, Qiming; Cheng, Ying; Chen, Jianhua; Lin, Xiaoyan; Wang, Yongsheng; Huang, Jianan; Cui, Jiuwei; Cao, Lejie; Liu, Yunpeng; Zhang, Yiping; Pan, Yueyin; Zhao, Jun; Wang, LiPing; Chang, Jianhua; Chen, Qun; Ren, Xiubao; Zhang, Wei; Fan, Yun; He, Zhiyong; Fang, Jian; Gu, Kangsheng; Dong, Xiaorong; Zhang, Tao; Shi, Wei; Zou, Jianjun; Bai, Xuejuan; Ren, Shengxiang; Zhou, Caicun |
| Aug-2021 | A phase 2 study of tislelizumab in combination with platinum-based chemotherapy as first-line treatment for advanced lung cancer in Chinese patients (vol 147, pg 259, 2020) | Wang, Zhijie; Zhao, Jun; Ma, Zhiyong; Cui, Jiuwei; Shu, Yongqian; Liu, Zhe; Cheng, Ying; Leaw, Shiang J.; Wu, Yanjie; Ma, Yan; Tan, Wei; Ma, Xiaopeng; Zhang, Yun; Wang, Jie |
| 2024 | SAFFRON-103: a phase Ib study of sitravatinib plus tislelizumab in anti-PD-(L)1 refractory/resistant advanced melanoma | Wang, Xuan; Pan, Hongming; Cui, Jiuwei; Chen, Xiao; Yoon, Won-Hee; Carlino, Matteo S.; Li, Xin; Li, Hui; Zhang, Juan; Sun, Jingchao; Guo, Jun; Cui, Chuanliang |
| Sep-2022 | Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blin | Lu, Shun; Wu, Lin; Jian, Hong; Chen, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Sun, Meili; Han, Liang; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Li, Baolan; Pan, Yueyin; Li, Xingya; Ye, Feng; Liu, Anwen; Wang, Ke; Cang, Shundong; Zhou, Hui; Sun, Xing; Ferry, David; Lin, Yong; Wang, Shuyan; Zhang, Wen; Zhang, Chengli |
| Jul-2023 | Sintilimab plus chemotherapy for patients with EGFR- mutated non-squamous non-small-cell lung cancer with disease progression after EGFRtyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double- blind, randomised, placebo-control | Lu, Shun; Wu, Lin; Jian, Hong; Cheng, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Han, Liang; Sun, Meili; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Wang, Ke; Li, Baolan; Li, Xingya; Ye, Feng; Liu, Anwen; Pan, Yueyin; Cang, Shundong; Zhou, Hui; Sun, Xing; Shen, Yuping; Wang, Shuyan; Zhang, Wen; He, Yue |
| Jul-2023 | Sintilimab plus chemotherapy for patients with EGFR- mutated non-squamous non-small-cell lung cancer with disease progression after EGFRtyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double- blind, randomised, placebo-control | Lu, Shun; Wu, Lin; Jian, Hong; Cheng, Ying; Wang, Qiming; Fang, Jian; Wang, Ziping; Hu, Yanping; Han, Liang; Sun, Meili; Miao, Liyun; Ding, Cuimin; Cui, Jiuwei; Wang, Ke; Li, Baolan; Li, Xingya; Ye, Feng; Liu, Anwen; Pan, Yueyin; Cang, Shundong; Zhou, Hui; Sun, Xing; Shen, Yuping; Wang, Shuyan; Zhang, Wen; He, Yue |
| Feb-2022 | Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): interim and final analyses of a double-blind, randomised, phase 3 clinical trial | Zhou, Caicun; Wang, Ziping; Sun, Yuping; Cao, Lejie; Ma, Zhiyong; Wu, Rong; Yu, Yan; Yao, Wenxiu; Chang, Jianhua; Chen, Jianhua; Zhuang, Wu; Cui, Jiuwei; Chen, Xueqin; Lu, You; Shen, Hong; Wang, Jingru; Li, Peiqi; Qin, Mengmeng; Lu, Dongmei; Yang, Jason |
| 2024 | Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial | Jiang, Zefei; Ouyang, Quchang; Sun, Tao; Zhang, Qingyuan; Teng, Yuee; Cui, Jiuwei; Wang, Haibo; Yin, Yongmei; Wang, Xiaojia; Zhou, Xin; Wang, Yongsheng; Sun, Gang; Wang, Jingfen; Zhang, Lili; Yang, Jin; Qian, Jun; Yan, Min; Liu, Xinlan; Yi, Tienan; Cheng, Ying; Li, Man; Zang, Aimin; Wang, Shusen; Wang, Chuan; Wu, Xinhong; Cheng, Jing; Li, Hui; Lin, Ying; Geng, Cuizhi; Gu, Kangsheng; Xie, Chunwei; Xiong, Huihua; Wu, Xiaohong; Yang, Junlan; Li, Qingshan; Chen, Yiding; Li, Fanfan; Zhang, Anqin; Zhang, Yongqiang; Wu, Yudong; Nie, Jianyun; Liu, Qiang; Wang, Kun; Mo, Xueli; Chen, Lilin; Pan, Yueyin; Fu, Peifen; Zhang, Helong; Pang, Danmei; Sheng, Yuan; Han, Yunwei; Wang, Hongxia; Cang, Shundong; Luo, Xianming; Yu, Wenbo; Deng, Rong; Yang, Chaoqiang; Keegan, Patricia |
